What is BergaMet NA?
BergaMet North America operates as a specialized leader in the U.S. supplement sector, focusing primarily on high-potency Calabrian citrus bergamot formulations. By bridging the gap between traditional botanical wisdom and modern clinical science, the company addresses critical health verticals including cardiovascular maintenance, cholesterol management, and metabolic equilibrium. Their product suite is engineered for health-conscious consumers who prioritize purity and evidence-based efficacy in their wellness regimens. As the company matures, it continues to refine its supply chain and distribution channels to maintain its status as a premium provider of natural health solutions.
How much funding has BergaMet NA raised?
BergaMet NA has raised a total of $39K across 1 funding round:
Debt
$39K
Debt (2021): $39K with participation from PPP
Key Investors in BergaMet NA
PPP
Public-Private Partnership
What's next for BergaMet NA?
The recent influx of capital signals a strategic pivot toward aggressive market expansion and product diversification. Having established a robust foundation in the cardiovascular health segment, BergaMet NA is expected to leverage these resources to enhance its research and development capabilities, potentially exploring new delivery mechanisms for its core bergamot extracts. Furthermore, the company is likely to invest in broader retail partnerships and digital marketing infrastructure to capture a larger share of the growing wellness market. By focusing on operational scalability and brand authority, BergaMet NA aims to solidify its leadership position while navigating the complexities of the dietary supplement industry.
See full BergaMet NA company page
